WMRI-PD-001 · Version 1
Comparing motor outcomes in two Parkinson’s trials
Research lead Robert Jones ·
What the comparison found The two trials used the same motor scale but assessed it at different times and in different medication states. We report their estimates separately.
Source status The Lancet issued an Expression of Concern for Exenatide-PD3 in June 2026. Its numbers below are the published values under that notice. The pilot draws no efficacy conclusion from that report.
Protocol
Question. Do the primary motor outcomes in LIXIPARK and Exenatide-PD3 measure change under comparable conditions?
Corpus. The two trials were selected from the Waddell archive. The extraction uses public aggregate results from the original articles, trial registrations, and linked journal notices. This is a focused comparison of two records. A systematic search or individual participant analysis falls outside this pilot’s scope.
Extraction rule. Record the randomized count, observations used in the primary analysis, phase, assessment time, medication state, and the published between-group estimate with its 95% confidence interval. Standardize direction to active treatment minus placebo by reversing the sign and interval limits when necessary. Higher motor scores indicate greater impairment.
Comparison rule. Compare assessment conditions and report estimates side by side. Keep post-washout secondary assessments separate. Record corrections and editorial notices alongside any affected result.
Evidence table
Estimates are in points on the MDS-UPDRS Part III motor scale. Confidence intervals come from the trial reports.
| Measure | LIXIPARKPhase 2 · 2024 | Exenatide-PD3Phase 3 · 2025 |
|---|---|---|
| Randomized | 156 · 78 per group | 194 · 97 per group |
| Primary analysis | 77 lixisenatide and 75 placebo with an available primary outcome | 92 exenatide and 96 placebo with at least one follow-up |
| Primary assessment | 12 monthsOn usual Parkinson’s medication | 96 weeksOff dopaminergic medication |
| Active minus placebo | −3.0895% CI −5.30 to −0.86. Sign reversed from the published estimate. | +0.9295% CI −1.56 to +3.39. Published adjusted estimate under editorial concern. |
| Sources | Original paperTrial registrationArchive record | Original paperTrial registrationArchive record |
LIXIPARK also reported a secondary motor assessment after its two-month study-drug washout. Exenatide-PD3’s primary off-medication assessment refers to dopaminergic medication. Differences in study drug, population, follow-up, and assessment conditions prevent these estimates from establishing a comparative or class-wide treatment effect.
Independent review and corrections
Version 1 contains the dated protocol and first extraction. Independent review is pending. The next reviewer should check source status, participant counts, medication-state definitions, and the estimate conversion. Any later decision or correction belongs in a dated version linked from the project register.